In recent years, the anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) and against programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) have gradually become the focus of research and development and have fully proven their potential as “cancer killers”. The gene discussed is CTLA4; the disease is cancer.